Reasons to Retain Envista Stock in Your Portfolio for Now

Zacks12-12

Envista Holdings Corporation’s NVST rise in the third quarter of 2024 is backed by robust growth within the Specialty Products and Technologies business. Strategic acquisition deals look promising for...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490738633?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","is_english":true,"pubTime":"2024-12-12 19:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490738633","market":"us","top_or_hot":-1,"title":"Reasons to Retain Envista Stock in Your Portfolio for Now","media":"Zacks","content":"<div>\n<p>Envista Holdings Corporation’s NVST rise in the third quarter of 2024 is backed by robust growth within the Specialty Products and Technologies business. Strategic acquisition deals look promising for...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-envista-stock-portfolio-114300435.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reasons to Retain Envista Stock in Your Portfolio for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReasons to Retain Envista Stock in Your Portfolio for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 19:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/reasons-retain-envista-stock-portfolio-114300435.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Envista Holdings Corporation’s NVST rise in the third quarter of 2024 is backed by robust growth within the Specialty Products and Technologies business. Strategic acquisition deals look promising for...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-envista-stock-portfolio-114300435.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEN","symbol_name":"Penumbra Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/reasons-retain-envista-stock-portfolio-114300435.html","article_id":"2490738633","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490738633","pubTimestamp":1734003780,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Envista Holdings Corporation’s NVST rise in the third quarter of 2024 is backed by robust growth within the Specialty Products and Technologies business. Strategic acquisition deals look promising for growth. Meanwhile, a debt-burdened balance sheet and dull macroeconomic environment remain concerns for NVST’s operations.In the past year, this Zacks Rank #3  company’s shares have lost 8.8% against 17.3% growth of the industry. The S&P 500 composite rose 30.8% during the same time frame.The leading MedTech company has a market capitalization of $3.53 billion. Envista delivered an earnings surprise of 33.33% in the third quarter of 2024.Poor Macroeconomic Condition: Envista has been grappling with deteriorating international trade with global inflationary pressure leading to a challenging situation related to raw material and labor costs as well as freight charges and rising interest rates. Additionally, Russia’s invasion of Ukraine and the global response to this invasion, including san","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEN":"Penumbra Inc","BK4548":"巴美列捷福持仓","NVST":"Envista Holdings","HAE":"美国血液技术","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4082":"医疗保健设备","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","BK4198":"医疗保健用品","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","GMED":"Globus Medical Inc","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC"},"translate_title":"目前将Envista股票保留在您的投资组合中的原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"NVST":1,"HAE":1,"GMED":0.9},"content_text":"Envista Holdings Corporation’s NVST rise in the third quarter of 2024 is backed by robust growth within the Specialty Products and Technologies business. Strategic acquisition deals look promising for growth. Meanwhile, a debt-burdened balance sheet and dull macroeconomic environment remain concerns for NVST’s operations.  \nIn the past year, this Zacks Rank #3 (Hold) company’s shares have lost 8.8% against 17.3% growth of the industry. The S&P 500 composite rose 30.8% during the same time frame.\nThe leading MedTech company has a market capitalization of $3.53 billion. Envista delivered an earnings surprise of 33.33% in the third quarter of 2024.\nFactors Benefiting Envista Stock\nSpecialty Products and Technologies Business Grows:  Envista’s Speciality Products & Technologies business has been gaining momentum on the back of strategic development, manufacturing and marketing of dental implant systems, including re-generative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The company is particularly gaining from growth within the Spark manufacturing technology. Envista recognized Spark to be its fastest-growing segment.The company’s orthodontic business grew mid-single digits in the third quarter, excluding Spark deferred revenues. The brackets and wire business experienced robust growth in Russia and China. Additionally, its value implant business witnessed mid-single-digit growth and an improving trend in Nobel. \nStrategic Acquisitions to Drive Growth: Envista's growth strategy anticipates future acquisitions and it continuously assesses potential buys that either strategically complement the company’s current portfolio or broaden it into new and lucrative economic sectors.Envista recently acquired Osteogenics Biomedical, the developer of innovative regenerative solutions for periodontists, oral & maxillofacial surgeons and clinicians involved in implant dentistry throughout the world.During the third quarter, DEXIS (currently operates as part of the Envista Equipment and Consumables segment) introduced several new offerings, including a new CBCT platform, enhanced software for the DEXIS intraoral scanner and additional surgical functionality in the DTX treatment planning platform. Management remains confident about DEXIS being a long-term growth driver for Envista.\nFactors Weighing on Envista Stock\nPoor Macroeconomic Condition: Envista has been grappling with deteriorating international trade with global inflationary pressure leading to a challenging situation related to raw material and labor costs as well as freight charges and rising interest rates. Additionally, Russia’s invasion of Ukraine and the global response to this invasion, including sanctions imposed by the United States and other countries, could hurt the company’s overall business.These challenging macroeconomic conditions are resulting in a significant escalation in the company’s costs and expenses. During the third quarter of 2024, Envista’s SG&A expenses rose 5.1%. The company’s operating profit plummeted 75% year over year. Envista’s business was adversely impacted by exiting lower priority and more price-sensitive geographic markets in the third quarter. Sales of the Specialty Product and Technology and the Equipment and Consumable segment declined 5.2% and 5.6%, respectively, year over year. \nImage Source: Zacks Investment Research\nWeak Solvency and Leveraged Balance Sheet: Envista ended the third quarter of 2024 with cash and cash equivalents of $991.3 million. Long-term debt totaled $1.31 billion, which was much higher than the quarter-end cash and cash equivalent level, indicating weak solvency. Meanwhile, the company had a short-term debt of $116 million at the end of the third quarter of 2024. The quarter’s total debt to capital was 31.6%, a moderately high level, indicating a leveraged balance sheet. \nNVST Stock Estimate Trend\nThe Zacks Consensus Estimate for 2024 earnings per share has moved north 1.4% to 72 cents in the past 30 days.\nThe Zacks Consensus Estimate for 2024 revenues is pegged at $2.50 billion, implying a 2.5% decline from the year-ago reported number.\nKey Pick\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Penumbra PEN and Globus Medical GMED.\nHaemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. HAE’s shares have risen 3.6% compared with the industry’s 19.9% growth in the past year.\nHAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nPenumbra, carrying a Zacks Rank #2 at present, has an estimated 2024 earnings growth rate of 33.5% compared with the industry’s 15.9%. Shares of Penumbra have risen 3.2% compared with the industry’s 14.5% growth in the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.\nGlobus Medical, carrying a Zacks Rank #3 at present, has a long-term estimated growth rate of 14.1%. Shares of the company have rallied 81.8% compared with the industry’s 14.5% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nEnvista Holdings Corporation (NVST) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490738633"}